Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic
Lymphocytic Leukemia
A continuing education article for nurse practitioners, physician assistants, clinical
nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists,
and physicians.
Release date: September 15, 2015
Expiration date: September 15, 2016
Expected time to complete this activity as designed: 0.50 hours
Meniscus Educational Institute
3131 Princeton Pike,
Building 1, Suite 205A
Lawrenceville, NJ 08648
Voice: 609-246-5000
Fax: 609-449-7969
E-mail: lrubin@meniscusedu.com
Journal of the Advanced Practitioner in Oncology
37 Main Street
Cold Spring Harbor, NY 11724
Voice: 631-692-0800
Fax: 631-692-0805
E-mail: claudine@harborsidepress.com
© 2015, Meniscus Educational Institute. All rights reserved.
Faculty
Gretchen Anne McNally, PhD, ANP-BC, The Ohio State University–Arthur G. James Cancer
Hospital
Jennifer M. Long, APRN, Whittingham Cancer Center, Norwalk Hospital
Lynne R. Brophy, RN, TriHealth Cancer Institute
Maria R. Badillo, MSN, RN, University of Texas MD Anderson Cancer Center
Activity Rationale and Purpose
The purpose of this article is to provide advanced practitioners with important information
about new treatment options for mantle cell lymphoma and chronic lymphocytic leukemia,
including novel oral agents, management of related side effects, and patient education.
Intended Audience
The activity’s target audience will consist of nurse practitioners, physician assistants,
clinical nurse specialists, advanced degree nurses, oncology and hematology nurses,
pharmacists, and physicians.
Learning Objectives
After completing this educational activity, participants should be able to:
Identify clinical features and considerations to determine which patients are eligible
for treatment with ibrutinib
Recognize potential side effects and adverse events associated with ibrutinib and
intervene to prevent, assess, and/or manage them appropriately should they occur
Continuing Education
Statement of Credit—Participants who successfully complete this activity (including
the submission of the post-test and evaluation form) will receive a statement of credit.
Physicians. The Meniscus Educational Institute is accredited by the Accreditation
Council for Continuing Medical Education (ACCME) to provide continuing medical education
for physicians.
The Meniscus Educational Institute designates this journal article for a maximum of
0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate
with the extent of their participation in the activity.
Nurses. This activity for 0.50 contact hours is provided by the Meniscus Educational
Institute.
The Meniscus Educational Institute is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.
Provider approved by the California Board of Registered Nursing, Provider No. 13164,
for 0.50 contact hours.
Pharmacists. The knowledge-based accredited education lectures are intended for pharmacists
involved in the care of cancer patients. This educational activity is sponsored by
the Meniscus Educational Institute.
The Meniscus Educational Institute is accredited by the Accreditation Council for
Pharmacy Education (ACPE) as a provider of continuing pharmacy education. The ACPE
Universal Activity Number assigned to this program, for 0.50 contact hours, is 0429-9999-15-015-H01-P.
Financial Disclosures
All individuals in positions to control the content of this program (eg, planners,
faculty, content reviewers) are expected to disclose all financial relationships with
commercial interests that may have a direct bearing on the subject matter of this
continuing education activity. Meniscus Educational Institute has identified and resolved
all conflicts of interest in accordance with the MEI policies and procedures. Participants
have the responsibility to assess the impact (if any) of the disclosed information
on the educational value of the activity.
Faculty
Gretchen Anne McNally, PhD, ANP-BC, has acted as a consultant and served on speakers
bureuas for Pharmacyclics.
Jennifer M. Long, APRN, has been a member of speakers bureaus for Celgene, Lilly,
and Pfizer.
Lynne R. Brophy, RN, has owned stock in Amgen and Johnson & Johnson.
Maria R. Badillo, MSN, RN, has nothing to disclose.
Lead Nurse Planner
Wendy J. Smith, ACNP, AOCN®, has nothing to disclose.
Planners
Jeannine Coronna has nothing to disclose.
Claudine Kiffer has nothing to disclose.
Terry Logan, CHCP, has nothing to disclose.
Pamela Hallquist Viale, RN, MS, CNS, ANP, has nothing to disclose.
Lynn Rubin has nothing to disclose.
Content Reviewers
Glenn Bingle, MD, PhD, FACP, has nothing to disclose.
Kate D. Jeffers, PharmD, BCOP, has nothing to disclose.
Margaret Fields, RN, ACNP-BC, AOCNP®, has nothing to disclose.
Wendy J. Smith, ACNP, AOCN®, has nothing to disclose.
Disclaimer
This activity has been designed to provide continuing education that is focused on
specific objectives. In selecting educational activities, clinicians should pay special
attention to the relevance of those objectives and the application to their particular
needs. The intent of all Meniscus Educational Institute educational opportunities
is to provide learning that will improve patient care. Clinicians are encouraged to
reflect on this activity and its applicability to their own patient population.
The opinions expressed in this activity are those of the faculty and reviewers and
do not represent an endorsement by Meniscus Educational Institute of any specific
therapeutics or approaches to diagnosis or patient management.
Product Disclosure
This educational activity may contain discussion of published as well as investigational
uses of agents that are not approved by the US Food and Drug Administration. For additional
information about approved uses, including approved indications, contraindications,
and warnings, please refer to the prescribing information for each product.
How to Earn Credit
To access the learning assessment and evaluation form online, www.meniscusce.com
Statement of Credit: Participants who successfully complete this activity (including
scoring of a minimum of 70% on the learning assessment and complete and submit the
evaluation form with an E-mail address) will be able to download a statement of credit.
ABSTRACT
Bruton’s tyrosine kinase (BTK) is expressed in B-cell malignancies, playing an important
role in B-cell receptor (BCR) signaling and offering a promising new strategy for
the development of targeted drugs. Malignant B cells in mantle cell lymphoma (MCL)
and chronic lymphocytic leukemia (CLL) rely on BCR signaling pathways for cell survival,
proliferation, adhesion, and migration. Ibrutinib, a first-in-class orally bioavailable,
small-molecule inhibitor of BTK, was approved in the United States for the treatment
of patients with relapsed or refractory MCL and CLL, as well as patients with CLL
who have deletion 17p. Ibrutinib has been shown to prevent proliferation and induce
apoptosis of malignant B cells while also blocking cellular responses to survival
stimuli from the tumor microenvironment. Ibrutinib has a favorable risk-benefit profile
and is effective in patients with relapsed or refractory MCL and CLL, for whom treatment
options are limited. Advanced oncology providers play a critical role in explaining
the mechanism of action of this novel oral agent, educating patients and caregivers
on successful self-administration of ibrutinib within the clinical setting, as well
as monitoring and managing potential side effects.
ARTICLE
Novel agents that target B-cell receptor (BCR) signaling pathways have afforded new
treatment options for patients with B-cell malignancies, providing important clinical
benefits in a number of hematologic tumor types. Ongoing studies continue to evaluate
the safety and effectiveness of these agents. Here, we focus on one such targeted
agent, the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (Imbruvica), and implications
for its use in the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic
leukemia (CLL).
Ibrutinib is a highly active new agent that is safe and effective in a heavily pretreated
and older adult population (Byrd et al., 2014a; Wang et al., 2013). On January 29,
2015, the US Food and Drug Administration (FDA) announced ibrutinib was the first
drug approved for the treatment of Waldenström’s macroglobulinemia. The use of ibrutinib
in patients with Waldenström’s macroglobulinemia is not discussed further in this
article, as very little clinical data was available at the time this article was written.
Overview of MCL and CLL
MCL is a rare yet well-defined subtype of B-cell lymphoma, accounting for 5% to 10%
of non-Hodgkin lymphomas (NHLs; Swerdlow, Campo, Seto, & Muller-Hermelink, 2008; Zaja,
Federico, Vitolo, & Zinzani, 2014). Patients with MCL have a median age of 60 to 65
years, with a male predominance of 2:1 (Swerdlow et al., 2008; Zaja et al., 2014).
Patients with MCL typically have advanced-stage disease, extensive lymphadenopathy,
splenomegaly, and bone marrow involvement, with or without peripheral blood involvement.
Extranodal sites often include the gastrointestinal tract (Swerdlow et al., 2008).
Mantle cell lymphoma is incurable with standard therapy and has a poor prognosis and
an aggressive clinical course characterized by resistant and relapsing disease (Zaja
et al., 2014). In November 2013, ibrutinib was approved by the FDA as single-agent
therapy in patients with MCL after at least one prior therapy (Pharmacyclics, 2014).
Chronic lymphocytic leukemia is the most commonly diagnosed leukemia in adults, with
a reported median age at diagnosis of 71 years (Howlader et al., 2013; Muller-Hermelink
et al., 2008). In 2013, CLL was diagnosed in nearly 16,000 persons and caused more
than 4,500 deaths (Howlader et al., 2013). Chronic lymphocytic leukemia usually affects
the peripheral blood and bone marrow, as well as the lymph nodes, liver, and spleen;
small lymphocytic leukemia (SLL) is considered part of the same entity, manifesting
primarily in the lymph nodes and spleen without peripheral lymphocytosis (Muller-Hermelink
et al., 2008).
Chronic lymphocytic leukemia remains incurable with current therapies and is generally
associated with an indolent disease course in patients with favorable prognostic factors
(median survival, 293 months). Patients with high-risk cytogenetics, including deletion
of the short arm of chromosome 17 (del 17p), have a more aggressive course and an
inferior prognosis than those without this abnormality (Hallek, 2013; Muller-Hermelink
et al., 2008). Treatment is typically deferred ("watch and wait") until clinical symptoms
develop, indicating a need for therapy (i.e., bulky lymphadenopathy and/or splenomegaly,
cytopenias, fevers without infection, drenching night sweats, profound fatigue, significant
unexplained weight loss). Factors considered in treatment decisions include age, performance
status, comorbidities, cytogenetics, and the therapeutic goal (disease control or
palliation).
Standard chemoimmunotherapy is not curative, and options for relapsed or refractory
CLL are often associated with increased toxicity (O’Brien et al., 2014). The need
to improve outcomes in older patients or those with high-risk disease remains. Ibrutinib,
an oral agent with a novel mechanism of action, was approved by the FDA as single-agent
therapy for patients with relapsed or refractory CLL and patients with CLL who have
del 17p, including both those who are treatment-naive and those who have received
prior therapy.
Background on BTK
External signals from the microenvironment are critical to B-cell malignancy development
and survival. The dependence of malignant B cells on these signals is complex and
highly variable. Genetic abnormalities allow for a proliferation advantage, whereas
dysfunctional microenvironments provide growth and drug-resistance signals. Apoptosis
may be prevented under such circumstances (Burger, Ghia, Rosenwald, & Calagaris-Cappio,
2009).
In 1952, Colonel Ogden Bruton diagnosed a lack of gamma globulins in a young boy with
primary immunodeficiency disease. The causative gene of X-linked agammaglobulinemia
was identified in 1993 and named Bruton agammaglobulinemia tyrosine kinase (Khan,
2012). An important kinase, BTK is positioned early in the BCR signaling pathway and
plays a critical role in the development, proliferation, apoptosis, and other cellular
processes of normal B cells. A number of B-cell malignancies overexpress BTK, causing
dysregulation of usual activities and making it a potential therapeutic target (Chung
& Lee, 2014; Robak & Robak, 2012).
Ibrutinib forms an irreversible covalent bond to cysteine 481, which blocks B-cell
activation and signaling. This process prevents proliferation, promotes apoptosis,
and stops the malignant cells’ response to prosurvival stimuli in the microenvironment
(Chung & Lee, 2014; Robak & Robak, 2012). Ibrutinib also inhibits several other kinases,
unlike idelalisib (Zydelig), another oral BCR inhibitor, which is a selective reversible
inhibitor of PI3Kẟ (Byrd, Jones, Woyach, Johnson, & Flynn, 2014b).
Clinical Trial Data
A phase I dose-escalation study of ibrutinib in 56 patients with relapsed/refractory
B-cell malignancies (NHL, CLL, SLL, or Waldenström’s macroglobulinemia) demonstrated
an overall response rate (ORR) of 60% (including 16% complete response) in 50 evaluable
patients, with grade 3 or 4 side effects occurring infrequently. The highest ORR was
reported in patients with MCL (7 of 9, 78%) and CLL (11 of 16, 69%; Advani et al.,
2013). Median progression-free survival (PFS) was 13.6 months for all patients in
this study.
Two different dosing schedules were examined, both using once-daily administration;
for 28 consecutive days, this regimen was followed by 7 days off (35-day cycle) or
continuous dosing until disease progression or unacceptable toxicity. The maximum
tolerated dose was not reached. This study indicated that continuous once-daily ibrutinib
dosing has a tolerable safety profile and may be needed to maintain optimal antitumor
effects. Thus, continuous dosing was recommended for subsequent phase II ibrutinib
studies.
Breakthrough Therapy Designation is part of the 2012 FDA Safety and Innovation Act
intended to expedite the development and review of new drugs for serious or life-threatening
diseases. For the FDA to grant this designation, preliminary clinical evidence must
show that the drug demonstrates substantial improvement over existing therapies on
one or more clinically significant endpoints (FDA, 2013).
Breakthrough Therapy Designation for ibrutinib in patients with relapsed or refractory
MCL was granted in February 2013 (FDA, 2013), based on an international, multicenter,
open–label phase II study evaluating the efficacy and safety of ibrutinib in patients
with heavily pretreated MCL (median 3 prior therapies). Patients enrolled in this
study included those with (n = 50, 48 treated) and without (n = 65, 63 treated) prior
bortezomib treatment. All treated patients (n = 111) received a fixed, once-daily
oral dose of ibrutinib (560 mg). Treatment was continued until disease progression
or unacceptable toxicity was noted (Wang et al., 2013). Key findings at median follow-up
of 15.3 months included a 68% ORR (including 21% complete response) and a 17.5-month
median duration of response (Table 1).
Table 1
Key Results From Phase II Study of Ibrutinib in MCL (N = 111)
The Breakthrough Therapy Designation for ibrutinib in patients with CLL/SLL with del
17p was granted in April 2013 (FDA, 2013), based on a phase Ib/2 multicenter, open-label
study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib.
Results from the RESONATE trial, a multicenter, open-label, phase III study, were
released in June 2014.
The RESONATE trial randomized patients (N = 391) with relapsed or refractory CLL to
daily ibrutinib or ofatumumab (Arzerra), the anti-CD20 antibody. At a median follow-up
of 9.4 months, ibrutinib significantly improved PFS (88% at 6 months), and the median
duration of response was not reached (Byrd et al., 2014a). The median PFS was 8.1
months in the ofatumumab group. The OS at 12 months was 90% for the ibrutinib group
compared with 81% in the ofatumumab group. All responses were partial, as there were
no complete responses, and an additional 20% of the patients had a partial response
with lymphocytosis. Lymphocytosis is recognized as a class effect of BCR-targeting
agents. Ibrutinib was superior to ofatumumab in PFS and OS in all subgroups, including
del 17p, resistance to previous purine analog therapy, age, and prior treatment regimens
(Byrd et al., 2014a; Table 2).
Table 2
Key Results From Phase III RESONATE Trial of Ibrutinib vs. Ofatumumab in CLL
Few patients have progressed while taking ibrutinib, and ibrutinib relapse often occurs
in the setting of Richter’s transformation and less frequently in CLL progression
(Byrd et al., 2014b). Understanding the resistance mechanism is important for developing
successful salvage therapies.
Studies suggest the primary mutation C481S in BTK prevents the drug from covalent,
irreversible drug binding. Three mutations were also discovered in PLCy2, including
S707Y, R665W, and L845F (Woyach et al., 2014a). Patients with more genomic instability,
such as del 17p or a complex karyotype, may be at higher risk for developing resistance
to ibrutinib. Most likely other mechanisms of resistance are also present, and this
topic is currently being explored further (Woyach et al., 2014a). Byrd et al. (2014b)
reported that discontinuing ibrutinib therapy may result in rapid disease progression
in relapsing patients, and instead they recommended continuing ibrutinib therapy until
immediately before the next treatment.
Dosing and Administration
Ibrutinib dosing for patients with MCL is 560 mg (four 140-mg capsules) orally once
daily, whereas dosing for patients with CLL is 420 mg (three 140-mg capsules) orally
once daily. The capsules should not be opened, broken, or chewed and should be taken
with a glass of water at approximately the same time each day. If a dose is missed,
it should be taken as soon as possible on the same day, and the patient should return
to the normal schedule the next day. If a dose is accidentally skipped, extra capsules
should not be taken.
Ibrutinib therapy should be interrupted for any grade ≥ 3 nonhematologic toxicity,
grade ≥ 3 neutropenia with infection or fever, or grade 4 hematologic toxicities.
Once the symptoms of the toxicity have resolved to grade 1 or baseline (recovery),
ibrutinib therapy may be reinitiated. Recommended dose modifications for these toxicities
are shown in Table 3 (Pharmacyclics, 2014).
Table 3
Recommended Ibrutinib Dose Modifications for Toxicity in MCL and CLL
Ibrutinib is primarily metabolized in the liver by CYP3A. Ibrutinib exposure data
for patients with impaired hepatic function are not currently available. Thus, its
use should be avoided in patients with baseline hepatic impairment (Pharmacyclics,
2014).
Examples of moderate CYP3A inhibitors are ciprofloxacin, diltiazem, fluconazole, and
verapamil, among others. Grapefruit juice and Seville oranges, which are known to
inhibit CYP3A, should also be avoided. Strong inducers of CYP3A can decrease the concentration
of ibrutinib by approximately tenfold; thus, coadministration of CYP3A inducers should
be avoided. Such agents include carbamazepine, rifampin, phenytoin, and St. John’s
wort (Pharmacyclics, 2014; U.S. FDA, 2014). Patients should be advised to inform their
health-care provider of all concomitant medications, including prescription and over-the-counter
drugs, vitamins, and herbal products.
Interruption of ibrutinib therapy should be considered for short-term use of strong
CYP3A inhibitors (e.g., antifungals or antibiotics such as voriconazole or clarithromycin
for < 7 days). If chronic coadministration of moderate CYP3A inhibitor is necessary,
the dose of ibrutinib should be decreased to 140 mg daily (1 capsule), and patients
should be closely monitored for symptoms of ibrutinib toxicity.
Lymphocytosis
Ibrutinib causes a rapid decrease in lymphadenopathy, and a simultaneous shift of
lymphocytes to the peripheral blood results in transient lymphocytosis (Byrd et al.,
2013; Wang et al., 2013). Inhibition of BTK may also impair adhesion of B cells in
the bone marrow and nodal sites, potentially contributing to the mobilization of malignant
cells to blood (Advani et al., 2013; de Rooij et al., 2012; Woyach et al., 2014b).
Patients with MCL who develop lymphocytosis (absolute lymphocyte count > 400,000/µL)
have developed intracranial hemorrhage, lethargy, gait instability, and headache,
although some of these cases were in the setting of disease progression (Pharmacyclics,
2014).
Clinical studies with ibrutinib reported lymphocytosis in 77% of CLL patients, with
the onset of isolated lymphocytosis occurring during the first month of therapy and
resolving by a median of 23 weeks (Pharmacyclics, 2014). In contrast, a smaller percentage
of MCL patients developed lymphocytosis (33%), with the onset of isolated lymphocytosis
occurring during the first few weeks of therapy and resolving by a median of 8 weeks
(Pharmacyclics, 2014). Lymphocytosis in the setting of improvement in other disease
parameters should not be considered treatment failure or progressive disease in patients
receiving a BCR-targeting agent (Hallek et al., 2012). A landmark analysis evaluating
patients with persistent lymphocytosis at 1 year and patients who achieved responses
without lymphocytosis found similar PFS benefits in both groups (Woyach et al., 2014b).
Precautions
Hemorrhagic events (ranging from petechiae and bruising to intracranial hemorrhage)
have been reported in patients treated with ibrutinib, regardless of platelet counts.
Of 111 patients with MCL treated with ibrutinib, 4 had subdural hematomas (all grade
≤ 3) associated with falls, head trauma, or both. These patients also had received
either aspirin or warfarin therapy within 2 days of the bleeding event (Wang et al.,
2013). The RESONATE study excluded patients requiring warfarin but not other forms
of anticoagulation. Major hemorrhage was similar between the two study groups, with
one subdural hematoma noted in a patient receiving ibrutinib. Mild bleeding episodes
were more common in the ibrutinib group (Byrd et al., 2014a).
Patients should be monitored for bleeding and assessed for concomitant use of fish
oil, vitamin E, flaxseed, and other over-the-counter and prescription medications
known to affect platelet function (Table 4). To minimize bleeding risks in patients
receiving ibrutinib therapy, the risks and benefits of concomitant use of antiplatelet
and anticoagulant medications should be weighed. In addition, withholding ibrutinib
should be considered for at least 3 to 7 days before and after surgery, depending
on the risk of associated bleeding (Pharmacyclics, 2014).
Table 4
Monitoring and Managing Potential Side Effects With Ibrutinib Therapy
Grade ≥ 3 infections occurred in at least 25% of patients with MCL and 24% of patients
with CLL who were treated with ibrutinib (Byrd et al., 2014a; Pharmacyclics, 2014).
Infectious events included sepsis and bacterial, fungal, or viral infections, which
have been associated with hospitalization and death. Antibiotic and antiviral prophylaxis
may be indicated in select patients. Administration of intravenous immunoglobulin
G (IVIG) in patients with hypogammaglobulinemia (for recurrent infections and if IgG
levels < 500 mg/dL) can minimize the possible development of infectious complications
(National Comprehensive Cancer Network, 2014). The importance of frequent hand hygiene
should be stressed. Patients and caregivers should be instructed to report symptoms
of infection, such as fever and chills, promptly for appropriate assessment and treatment
(Table 4).
In the RESONATE trial, atrial fibrillation was noted in 10 patients in the ibrutinib
group, leading to the discontinuation of ibrutinib in one patient. One patient developed
atrial fibrillation in the ofatumumab group. Potential reasons for atrial fibrillation
occurring among patients receiving ibrutinib are being explored (Byrd et al., 2014a).
Treatment-emergent grade 3 or 4 cytopenias were reported in 41% of patients with MCL
who were treated with ibrutinib (29% neutropenia, 17% thrombocytopenia, 9% anemia).
Grade 3 or 4 cytopenias also occurred in the RESONATE trial with CLL patients and
was similar between the ibrutinib and ofatumumab arms (ibrutinib: 16% neutropenia,
6% thrombocytopenia, 6% anemia; ofatumumab: 14% neutropenia, 4% thrombocytopenia,
8% anemia). Monthly laboratory evaluation for complete blood cell counts is recommended
(Byrd et al., 2014a; Pharmacyclics, 2014).
Side-Effect Management
Diarrhea is the most frequently reported adverse event associated with ibrutinib,
affecting 50% of patients with MCL and 48% of patients with CLL treated in clinical
trials; the majority of these cases were grade 1 or 2 events, and ibrutinib therapy
was not discontinued because of diarrhea (Byrd et al., 2013; Byrd et al., 2014a; Wang
et al., 2013). Moreover, colitis was not reported in the aforementioned clinical trials
with ibrutinib.
Patients and caregivers should anticipate diarrhea, and they should be informed of
appropriate dietary and pharmacologic interventions, including the importance of aggressive
oral hydration (Table 4). Electrolytes should be monitored for imbalances and treated
appropriately. Patients should be instructed to contact their health-care team if
diarrhea persists.
Fatigue, mostly grade 1 or 2, was reported in 41% of patients with MCL and 28% of
patients with CLL treated in clinical trials with ibrutinib (Byrd et al., 2014a; Wang
et al., 2013). Fatigue is frequently reported by patients with cancer, with a profound
negative impact on patient outcomes, including symptom distress and decreased quality
of life (Borneman, 2013; Mitchell, Beck, Hood, Moore, & Tanner, 2007).
Nonpharmacologic interventions such as low-impact exercise have been shown to improve
cancer-related fatigue, and evidence supports approaches such as education regarding
energy conservation and activity management (Borneman, 2013; Mitchell et al., 2007).
Referrals for physical, occupational, and psychosocial therapies may be beneficial
(Borneman, 2013; Table 4).
Implications for Clinical Practice
Advanced oncology practitioners play a critical role in providing guidance and education
to patients and caregivers on the successful self-administration of ibrutinib and
in explaining the mechanism of action of this novel oral agent. Patients have an increased
responsibility for self-administered therapies, and serious consequences can occur
with poor management or nonadherence, including severe side effects, disease progression,
or even death (Yagasaki & Komatsu, 2013).
Patients with MCL and CLL tend to be older and may face unique challenges, such as
diminished physical and cognitive capabilities, increased risk of drug interactions,
polypharmacy, and adverse events related to comorbid conditions. Anticipating patient
needs to allow for early intervention and proactive care is essential. Provider support
also includes coordinated effort and close collaborations with other members of the
health-care team, as well as provision of psychological and emotional support to further
encourage patient empowerment and self-management (Yagasaki & Komatsu, 2013).
Conclusion
BCR signaling pathways present a new class of promising therapeutic targets. Ibrutinib
is a first-in-class oral BTK inhibitor. Approval of ibrutinib offers a novel, effective
oral treatment option in patients with relapsed or refractory MCL and CLL, as well
as for both treatment naive and relapsed CLL with del 17p. Ibrutinib has a favorable
toxicity profile and can be safely administered in a heavily pretreated and older
adult population. This single agent induced a high response rate and durable remissions
in both MCL and CLL (Byrd et al., 2013; Byrd et al., 2014a; Wang et al., 2013). Ibrutinib
offers a new, effective treatment option for patients who typically have a poor prognosis
and few other treatment options available.
Acknowledgments
The authors sincerely thank Pam Commike, PhD, and Patricia Y. Ryan, PhD, RN, AOCN®,
for their helpful discussions. We also thank Pharmacyclics for review of the manuscript
for data accuracy and supporting the medical writing assistance of Robert Rydzewski,
MS, CMPP.